Laura Rosa Brunet, Immodulon’s Chief Scientific Officer, published in Journal for ImmunoTherapy of Cancer

Immodulon’s Chief Scientific Officer, Laura Rosa Brunet, has been an active participant of Working Group 4 (WG4) of the Society of Immunotherapy of Cancer (SITC) Immune Biomarkers Task Force, whose work has been published in the prestigious Journal for ImmunoTherapy of Cancer (JITC).

The SITC Immune Biomarkers Task Force was asked to investigate predictive and prognostic biomarkers of response to cancer immunotherapy. The final aim was to provide an up to date review of developments, identify current obstacles and make recommendations for future implementations. Because of the challenging undertaking, the Task Force was split into four Working Groups, each focussing on distinct aspects of immune biomarker development. WG4 concentrated on clinical outcome predictions using baseline immune-related measures, both in the periphery as well as at the tumour site, to drive biomarker identification and clarify why response to cancer immunotherapy is limited to a subset of patients.

The resulting recommendations of this Task Force were presented last year at a meeting in Bethesday, USA - held by SITC, in collaboration with the National Cancer Institute. The findings of WG4 are now available to read online.

To read the findings of Laura and her fellow researchers, please see the below link to the article: “Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy.”

Journal for ImmunoTherapy of Cancer